SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022

[December 19, 2013]

Research and Markets: Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/2fwx36/fasiglifam_type) has announced the addition of the "Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022" report to their offering.

Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period.

The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Fasiglifam (TAK-875) is a first-in-class GPR40/FFAR1 receptor agonist, currently being investigted in Phase III clinical trials by Takeda Pharmaceutical Company.


Scope

- Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Fasiglifam including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Fasiglifam for the top ten countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Fasiglifam performance

- Obtain sales forecast for Fasiglifam from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

Key Topics Covered:

List of Tables

List of Figures

Introduction

Disease Overview

Disease Management

Competitive Assessment

Opportunity and Unmet Need

Pipeline Assessment

Fasiglifam (TAK-875)

Appendix

For more information visit http://www.researchandmarkets.com/research/2fwx36/fasiglifam_type

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.